Synlogic Inc. (SYBX) PT Lowered to $14 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Synlogic Inc. (SYBX) PT Lowered to $13 at H.C. Wainwright
August 21, 2019 7:17 AM EDTH.C. Wainwright analyst Raghuram Selvaraju lowered the price target on Synlogic Inc. (NASDAQ: SYBX) to $13.00 (from $22.00) while maintaining a Buy rating.
... MoreSynlogic Inc. (SYBX) PT Lowered to $6 at Jefferies
August 21, 2019 4:16 AM EDTJefferies analyst Chris Howerton lowered the price target on Synlogic Inc. (NASDAQ: SYBX) to $6.00 (from $18.00) while maintaining a Buy rating.
The analyst comments "After failing to show the efficacy of '1020 in patients, SYBX announced today that it will discontinue... More
Citi Double Downgrades Synlogic Inc. (SYBX) to Sell
August 21, 2019 4:15 AM EDTCiti analyst Yigal Nochomovitz downgraded Synlogic Inc. (NASDAQ: SYBX) from Buy to Sell with a price target of $2.00 (from $20.00).
Says SYNB1020 failure yields little confidence in Synthetic Biotic Platform.Removes product revenues from model for SYNB1020 and... MoreOppenheimer Downgrades Synlogic Inc. (SYBX) to Perform
August 20, 2019 4:07 PM EDTOppenheimer analyst Mark Breidenbach downgraded Synlogic Inc. (NASDAQ: SYBX) from Outperform to Perform.
The analyst comments "Tuesday, Synlogic announced interim results from a Phase 1b/2a trial of SYNB1020 in patients with elevated ammonia. While SYNB1020 showed biomarker-based evidence of ammonia turnover, no... More
Synlogic Inc. (SYBX) PT Lowered to $10 at Piper Jaffray
August 20, 2019 10:24 AM EDTPiper Jaffray analyst Edward Tenthoff lowered the price target on Synlogic Inc. (NASDAQ: SYBX) to $10.00 (from $20.00) while maintaining a Overweight rating.
... MoreUPDATE: Synlogic Inc. (SYBX) PT Lowered to $9.50 at Chardan
August 20, 2019 9:52 AM EDT(Updated - August 20, 2019 9:53 AM EDT)
(update corrects broker)
Chardan analyst Taylor Feehley lowered the price target on Synlogic Inc. (NASDAQ: SYBX) to $9.50 (from $25.00) while maintaining a Buy rating after the company announced the discontinuation of SYNB1020.
... MorePre-Open Movers 08/20: (HGV) (JCP) (BIDU) Higher; (SYBX) (SRPT) (FN) Lower (more...)
August 20, 2019 9:16 AM EDTToday's Pre-Open Movers
Synlogic (NASDAQ: SYBX) 21% LOWER; announced that it is discontinuing development of SYNB1020, an early stage clinical product candidate for the treatment of hyperammonemia. The decision to discontinue the program was based on top-line data from an interim analysis of a randomized, double-blind, placebo-controlled Phase 1b/2a study of the Synthetic Biotic medicine in 23 patients with cirrhosis and elevated blood ammonia. The study was designed to evaluate the safety and tolerability of SYNB1020 treatment, as well as changes in blood ammonia levels and several exploratory endpoints... More
Synlogic (SYBX) Discontinuing Development of SYNB102
August 20, 2019 9:04 AM EDTSynlogic, Inc., (Nasdaq: SYBX) announced that it is discontinuing development of SYNB1020, an early stage clinical... More
